Table of contents
- Trial overview
- Who is being studied
- Trial phases and design
- Main endpoints
- Trial details
- What the trial terms mean for patients
Trial overview
These clinical trials are studying AUTOLOGOUS GENETICALLY MODIFIED T LYMPHOCYTES TRANSDUCED WITH LENTIVIRUS EXPRESSING CAR PROTEIN DIRECTED AGAINST BCMA in blood cancers that involve plasma cells.[1] The studies are interventional, which means the research team gives a treatment and then watches what happens.[1]
Two authorised trials were provided: one in newly diagnosed primary plasma cell leukemia and one in relapsed/refractory multiple myeloma.[1][2] The trials are looking mainly at safety and how well the treatment works.[1][2]
Who is being studied
The first trial includes people with newly diagnosed primary plasma cell leukemia.[1] This is a rare and serious cancer of plasma cells, and the study is testing the treatment after initial therapy to help induce a response.[1]
The second trial includes people with relapsed/refractory multiple myeloma.[2] In simple words, relapsed means the disease came back, and refractory means it did not respond well to earlier treatment.[2] This study focuses on patients who already had 2 to 4 lines of therapy, meaning they have already received 2 to 4 different treatment regimens.[2]
Trial phases and design
The plasma cell leukemia study is a Phase 2 trial with 25 planned participants.[1] Phase 2 studies usually look for early signs that a treatment may help, while still checking safety carefully.[1]
The multiple myeloma study is a Phase 3 trial with 126 planned participants.[2] Phase 3 studies are larger and compare a new treatment with standard treatment to see which works better.[2]
Main endpoints
An endpoint is the main result a trial measures to see whether the treatment is helping.[1][2] The first trial has one main efficacy endpoint and one main safety endpoint.[1]
Overall response rate: the first trial measures how many patients have at least a partial response within the first 3 months after the first infusion.[1] A partial response means the cancer gets smaller or improves, but is not completely gone.[1]
Cytokine release syndrome and neurological toxicity: the first trial also measures how many patients develop these problems in the first 30 days after treatment.[1] Cytokine release syndrome is a strong immune reaction, and neurological toxicity means problems affecting the brain or nerves.[1]
Progression-free survival: the second trial measures the time patients live without the disease getting worse.[2] This is the main endpoint in the Phase 3 study.[2]
Trial details
The first trial is titled as a study of a humanized CART directed against BCMA (ARI0002h) in newly diagnosed primary plasma cell leukemia, and its brief summary says it is testing safety and efficacy after initial treatment to induce response.[1] The intervention list includes AUTOLOGOUS GENETICALLY MODIFIED T LYMPHOCYTES TRANSDUCED WITH LENTIVIRUS EXPRESSING CAR PROTEIN DIRECTED AGAINST BCMA, along with several other medicines used in the treatment plan listed in the source data.[1]
The second trial compares academically produced CAR T cells with standard treatment in people with multiple myeloma that has returned or did not respond to earlier therapy.[2] Its brief summary says the goal is to compare progression-free survival in patients randomized to the CAR T-cell approach versus current standard of care.[2]
What the trial terms mean for patients
Authorised means the trial has been approved to start.[1][2] Interventional means patients receive a study treatment rather than only being observed.[1][2]
Enrollment means the number of people the study plans to include.[1][2] In these trials, the planned enrollment is 25 in the Phase 2 study and 126 in the Phase 3 study.[1][2]
Randomized means people are assigned to different study groups by chance.[2] This helps compare treatments in a fair way.[2]
